SLC2A1 and cancer: In targeted cancer therapy using GLUT, various glycoconjugates based on molecules such as oxaliplatin [23], chlorambucil [24], paclitaxel [25], adriamycin [26], azomycin [27], methotrexate [28], as well as derivatives of thiosemicarbazone [29] have been designed.